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Primary aldosteronism (PA) is the leading cause of secondary hypertension. The source of
aldosterone hypersecretion is often due to a unilateral aldosterone-producing adenoma,
and unilateral laparoscopic adrenalectomy is recommended in such patients. Before
surgery, confirmation of unilateral hypersecretion is necessary. This is optimally performed
by adrenal venous sampling (AVS). However, AVS is not always successful e.g., due
to difficulties in the cannulation of the right adrenal vein. Here we present the case
of a 53-year-old female patient with primary aldosteronism, a left-sided adrenal mass
and an inconspicuous right adrenal. AVS was performed, but cannulation of the right
adrenal vein failed. Therefore, aldosterone hypersecretion also of the right adrenal could
not be excluded despite higher aldosterone concentrations in the left renal and adrenal
vein. To increase the certainty that the left sided adrenal mass was the source of
aldosterone hypersecretion, steroid profiling was performed in a sample from the inferior
vena cava. This revealed markedly elevated levels of 18-oxocortisol, 18-hydroxycortisol,
11-deoxycorticosterone, and 11-deoxycortisol, a steroid profile that strongly suggested
that the left sided adrenal mass was an aldosterone producing adenoma, most likely
due to a somatic KCNJ5 mutation. Following unilateral adrenalectomy, CYP11B2
immunohistochemistry, and genetics analysis of the resected adrenal confirmed a solitary
aldosterone-producing adenoma with intense aldosterone synthase expression, which
harbored a previously described KCNJ5 Phe154Cys mutation. Biochemical and clinical
cure was confirmed 6 months postoperatively.
Keywords: primary aldosteronism, adrenal venous sampling, steroid profiling, aldosterone-producing adenoma,
somatic KCNJ5 mutation
BACKGROUND
The reported prevalence of primary aldosteronism in patients with hypertension in the general
population is around 6% (1). The prevalence in therapy resistant hypertension is over 15%,
making primary aldosteronism the most common cause of endocrine hypertension (2). The
source of aldosterone hypersecretion is frequently a unilateral adrenal adenoma (3), and unilateral
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laparoscopic adrenalectomy is recommended in such patients
(4). However, bilateral adrenal hyperplasia, nowadays more
frequent than unilateral aldosteronism, has to be excluded before
proceeding to surgery. In younger patients (age < 35 years) with
spontaneous hypokalemia and marked aldosterone excess, the
radiologic finding of a unilateral adrenal adenoma is regarded as
sufficient proof of an aldosterone producing adenoma. In other
patients the currently accepted gold standard for subtyping is
AVS, as recommended by guidelines (4). AVS is, however, not
always successful. In various studies the success rate of AVS varies
between 30 and 96% (5–7). Due to anatomic variation, most AVS
failures are due to failures of cannulation of the right adrenal
vein (8).
Steroid profiling is an emerging method, facilitated by
liquid chromatography with tandem mass spectrometry (LC-
MS/MS), that involves measurements of multiple steroids, which
in addition to aldosterone may include the hybrid steroids
18-hydroxycortisol and 18-oxocortisol (9). Previous studies
have shown that these hybrid steroids are higher in adrenal
venous samples from aldosterone-producing adenomas (APA)
compared to bilateral adrenal hyperplasia (BAH) (10, 11).
Furthermore, measurement of these metabolites could predict
the underlying mutation, especially the presence of a somatic
KCNJ5mutation in patients with APA (12). Here we demonstrate
a case where such steroid profiling helped to confirm a unilateral
adrenal adenoma following unsuccessful cannulation of the right
adrenal vein.
FIGURE 1 | Magnetic resonance imaging. Shown is a left-sided adrenal mass (arrows) with a maximum diameter of 2.3 cm. Only slight signal loss in the opposed
phase on Tl weighted-images. Mild contrast-enhancement in the periphery of the tumor. Multiple hepatic cysts. Tlw, T2w: Tl- or T2 weighted, respectively; TSE, turbo
spin echo; VIBE, volumetric interpolated breath-hold examination; FS, fat saturated; KM+, with contrast agent.
CASE PRESENTATION
A 53-year-old female presented in our outpatient clinic because
of repeatedly low serum potassium levels (2.3 to 2.6 mmol/l)
despite oral potassium supplementation. For more than 10
years she had received antihypertensive treatment, lately with
valsartane (160mg od) and lercanidipine (20mg od). She was not
on diuretic medication, did not eat liquorice and had no diarrhea.
Her records revealed that already 5 years before her presentation
in our outpatient clinic she had marked hypokalaemia (2.5 to
2.7 mmol/l).
We detected a suppressed plasma renin concentration
(1 ng/l; reference intervals 1.68–23.9 ng/l) and an elevated
plasma aldosterone (874 pg/ml; reference intervals 17.6–
232 pg/ml), resulting in an aldosterone-to-renin ratio of
874 (upper cut-off of reference intervals in our laboratory
< 17.5). After correcting the hypokalaemia and switching
antihypertensive therapy to doxazosine and lercanidipine, a
seated saline infusion test (2 l 0.9% over 4 h) was performed.
Plasma aldosterone concentrations were not sufficiently
suppressed (0 min: 1,070 pg/ml; 240 min: 731 pg/ml;
cut off < 50–100 pg/ml) (13), confirming the diagnosis of
primary aldosteronism. In a posture test, plasma aldosterone
concentrations did not change. An adrenal MRI demonstrated
a normal looking right adrenal and a left-sided adrenal mass
with a maximal diameter of 23mm, compatible with an adrenal
adenoma (Figure 1).
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Options of surgery or long-term mineralocorticoid receptor
antagonist therapy were discussed with the patient. We
recommended surgical resection of the adenoma as the best
option, this dependent on the confirmation that it was
the source of the aldosterone excess. Since the patient was
not principally opposed, AVS was conducted to exclude a
potential contralateral aldosterone hypersecretion (Table 1).
The adrenal to peripheral vein (inferior vena cava) cortisol
ratios were 1.72 and 10.72 on the right and left side,
respectively. With a cut off under cosyntropin stimulation
of >3 (14), this indicated that only the left adrenal vein
had been properly cannulated. The aldosterone concentration
and aldosterone to cortisol ratio was clearly highest in the
left adrenal, and also higher at all left renal vein locations
compared to those on the right side. Although this confirmed
hypersecretion by the left adrenal harboring the adenoma,
the failure to properly cannulate the right adrenal vein left
the possibility that there was also hypersecretion on the right
side (15).
At this point we looked for a further non-invasive
possibility to discriminate between APA and BAH, and
therefore performed steroid profiling of a remaining sample
taken from the inferior vena cava. Since the patient was
in no case willing to have a second AVS, we also started
mineralocorticoid receptor antagonist therapy to treat
hypertension and hypokalaemia as well as to prepare
her for surgery. The steroid profiling revealed markedly
elevated plasma concentrations of 18-oxocortisol, 18-
hydroxycortisol, 11-deoxycorticosterone, and 11-deoxycortisol
(Table 2), a constellation strongly indicating a somatic
KCNJ5 mutation in an aldosterone producing adenoma
(10, 11). Although initially reluctant with respect to surgery,
following these steroid profiling results and convincing her
that there now was little doubt that the adenoma of the
left adrenal was the source of aldosterone overproduction,
the patient underwent left-sided unilateral laparoscopic
adrenalectomy. The expected diagnosis of an aldosterone-
producing adenoma was confirmed by CYP11B2 (aldosterone
TABLE 1 | Adrenal venous sampling.
Localization Aldosterone
(pg/ml)
Cortisol
(µg/l)
Aldosterone/
Cortisol
Inferior vena cava 1,555 337 4.61
Hepatic vein 577 340 1.70
Right renal vein ostium 1,165 276 4.22
Right renal vein distal 1,375 327 4.21
Right renal vein middle 1,355 336 4.03
Right adrenal vein 1,815 579 3.14
Left renal vein ostium 4,260 596 7.15
Left renal vein distal 1,740 295 5.90
Left renal vein middle 4,840 433 11.18
Left adrenal vein 63,600 3,614 17.60
Continuous cosyntropin (ACTH) stimulation (50 mcg per hour) was started 30min before
and continued throughout sampling from the indicated veins. Shown are the respective
aldosterone and cortisol levels as well the aldosterone to cortisol ratio.
synthase) immunohistochemistry (Figure 2). Moreover,
direct Sanger sequencing of genomic DNA extracted from
10µm sections of the formalin-fixed paraffin-embedded
adrenal tissue corresponding to the adenoma revealed a
heterozygous missense mutation of the KCNJ5 gene (c.861T>G,
p.Phe154Cys; data not shown), described previously by
Scholl et al. (16).
Following adrenalectomy spironolactone therapy was
terminated. Blood pressure 3 weeks later was 132/86mm
Hg without any antihypertensive medication, potassium
was 4.8 mmol/l (3.5–5.5), and the aldosterone/renin ratio
was 2.14 (<20). Her primary care physician confirmed
that 6 months post surgery her blood pressure was
consistently <140/90mm Hg without medication, and
that her potassium concentration remained in the normal
range without any supplementation. According to the
PASO criteria this is a complete clinical and biochemical
success (17).
DISCUSSION
The finding of unilateral radiological features consistent with
an adrenal cortical adenoma is not regarded as sufficient proof
for a unilateral aldosterone producing adenoma in patients that
are older than 35 years (18). AVS is therefore recommended,
with lateralization of aldosterone hypersecretion commonly
assessed by calculation of the lateralization index using the
higher ratio of aldosterone to cortisol in one vein compared
TABLE 2 | Plasma steroid profiles from a blood sample obtained from the inferior
vena cava as determined by liquid chromatography with tandem mass
spectrometry (LC-MS/MS).
Steroid Concentration
(nmol/l)
Reference intervalsa
(nmol/l)
18-Oxocortisol *** 1.75 <0.09
18-Hydroxycortisol*** 21.0 0.4–3.4
Aldosterone** 2.36 0.02–0.67
11-Deoxycorticosterone** 3.90 <0.34
11-Deoxycortisol* 9.90 0.11–0.69
Corticosterone* 61.8 1.6–20.8
21-Deoxycortisol* 0.73 <0.22
Cortisol 720 121–700
Cortisone 40.8 25.0–69.9
Androstendione 5.55 0.83–5.62
DHEA 26.2 2.2–22.2
DHEAS 2912 911–6816
17OH-Progesterone 6.2 0.2–6.8
Testosterone 1.54 0.30–2.30
Pregnenolone 19.1 1.1–10.1
The presence of an APA due to a KCNJ5 mutation was indicated from the pattern
of increased plasma concentrations of steroids compared to previously reported sex
and/or age specific reference intervals (11). a,***indicates a steroid characteristically
more substantially increased in unilateral APAs due to KCNJ5 mutations than in other
unilateral APAs without KCNJ5 mutations or bilateral forms of primary aldosteronism;
**indicates a steroid usually increased more substantially in unilateral APAs than bilateral
primary aldosteronism; *indicates a steroid often increased in all subtypes of primary
aldosteronism compared to primary hypertensive populations.
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FIGURE 2 | Immunhistochemistry. The formalin-fixed paraffin-embedded adrenal corresponding to the adenoma was stained with HE (Left) or subjected to
CYP11B2 immunostaining (Right). Demonstrated is an intense CYP11B2 expression.
to the other (9). It is an invasive procedure, and even if
performed by an experienced radiologist in specific centers
it is, as in the present case, not always successful. Here we
demonstrate that in such situations steroid profiling can help
by providing evidence for the existence of an aldosterone
hypersecreting adenoma.
It has been previously shown that patterns of steroid
expression in APA are dependent of the underlying somatic
mutations (12), and in most cases differ from the pattern
seen in BAH (10, 11). In the present case, the substantially
increased levels of 18-oxocortisol and 18-hydroxycortisol in
the vena cava sample left little doubt that an APA with
a KCNJ5-mutation and not BAH caused the aldosteronism,
and thus helped us with the decision to remove the left
sided adenoma despite inconclusive AVS. The presence of the
KCNJ5 mutation was later confirmed in the biopsy. Due to
the lack of material we did not perform steroid profiling in
the adrenal or renal veins. Since the aldosterone concentration
and aldosterone/cortisol ratio in the left adrenal vein clearly
demonstrated hypersecretion on this side and the steroid profile
derived from the inferior vena cava was so clearly suggestive of
an APA, this would, however, have added little information in the
present case.
Steroid profiling through (LC-MS/MS) is non-invasive
and requires only a minimal volume of blood. On the
other hand, instrumentation is expensive and requires
a high level of expertise, with so far no available
prospective data (9). Potentially, steroid profiling will in
the future be a non-invasive tool that can help to avoid
AVS, at least in certain presentations of patients with
primary aldosteronism.
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